Prelude Therapeutics Inc
PRLD
Get informed when a big investor buys or sells
+ FollowMarket Cap$311.42M
Close$
$1.06
79.9% downside
Current Fair Value
79.9% downsideOvervalued by 79.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $311.42 Million |
|---|---|
| Enterprise Value | $327.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.29 |
| Beta | 0.94 |
| Outstanding Shares | 98,388,593 |
Return
| Return on Equity | -45.23% |
|---|---|
| Return on Assets | -31.94% |
| Return on Invested Capital | -43.07% |
Valuation & Multiples
| P/E Ratio | -6.92 |
|---|---|
| PEG | 12.49 |
| Price to Sales | - |
| Price to Book Ratio | 5.25 |
| Enterprise Value to Revenue | 14.63 |
| Enterprise Value to EBIT | -5.03 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$6.14 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.11
Average shareholder expectationRevenue Estimate
$35.33 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 21,000▲ Infinity% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.29%▼ 7.94% |
|---|---|
| Total Invested | $105.24M▲ 27.46% |
| Investors Holding | 56▲ 7.00% |
ESG Score
No data
About Prelude Therapeutics Inc
68 employeesPrelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhib...